ClinicalTrials.gg
RecruitingNCT07749417Updated Aug 6, 2026

Perioperative Transcutaneous Fluorescence Detection of GFR Trajectory for the Early Prediction and Diagnosis of CSA-AKI.

An observational study in Acute Kidney Injury, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by China National Center for Cardiovascular Diseases · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
436
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.

Planned enrollment
57th of 105
436 · median 472
Started
2026
with 24 others
Observational
105 of 168
26 open now
Primary completion
2029-07
later than 51 of 53 live
Registered
162nd of 168
by date
Lead sponsor
4 of 168
China National Center for Cardiovascular Diseases

Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 57th largest by planned enrollment of the 105 observational ones that give a count, is one of 25 that started in 2026, is one of 105 observational ones, reaches primary completion later than 51 of the 53 other live ones, and was the 162nd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Acute Kidney Injury with a site in China, or all of them as a file.
02

Study summary

brief summary:The goal of this observational study is to evaluate the value of perioperative transcutaneous fluorescence glomerular filtration rate (GFR) monitoring for the early prediction and diagnosis of cardiac surgery-associated acute kidney injury (CSA-AKI) and contrast-associated acute kidney injury(CA-AKI) in adult patients. The main questions it aims to answer are: Can perioperative GFR or peri-contast trajectories measured by a transcutaneous fluorescence monitoring system predict the development of CSA-AKI or CA-AKI before conventional diagnostic criteria are met? What changes in perioperative or peri-contast GFR trajectories are associated with the occurrence and severity of CSA-AKI or CA-AKI? Participants scheduled for cardiovascular surgery or contast-enhanced CT scan or PCI will undergo continuous perioperative transcutaneous GFR monitoring following intravenous administration of a fluorescent tracer. Clinical characteristics, perioperative or peri-contast hemodynamic data, laboratory measurements, imaging findings, and postoperative or post-contast outcomes will be collected to evaluate the predictive and diagnostic performance of perioperative or peri-contrast GFR trajectories for CSA-AKI or PC-AKI.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patients undergoing cardiovascular surgery or receiving iodinated contrast media who are at risk of acute kidney injury (AKI), as well as patients diagnosed with cardiac surgery-associated acute kidney injury (CSA-AKI) or contrast-associated acute kidney injury (CA-AKI), will be prospectively enrolled. Participants will undergo perioperative or peri-procedural transcutaneous glomerular filtration rate (GFR) monitoring to evaluate GFR trajectories for the early prediction and diagnosis of AKI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old;
  2. Specific inclusion criteria for the cohort:

    • trajectory characterization after cardiovascular surgery or Iodine contrast agent exposure: Patients scheduled for elective cardiovascular surgery or interventional cardiovascular surgery or CTA; ② GFR trajectory characterization of AKI: Patients with confirmed CSA-AKI or contrast-associated acute kidney injury (CA-AKI).

Exclusion criteria

Exclusion Criteria:

  1. Received renal replacement therapy before surgery or before contrast imaging, including kidney transplantation and regular dialysis;
  2. Serum creatinine > 353 μmol/L before surgery or before contrast imaging;
  3. Patients with AKI who did not recover before surgery or before contrast imaging;
  4. Patients with malignant tumors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
436 participants (estimated)
Patient registry
No

Groups and cohorts

  • Determination of GFR trajectories after cardiovascular surgery or contrast agent exposure

    Perform GFR testing on patients who are scheduled for cardiovascular surgery or who are going to receive contrast agents to determine the GFR trajectory after the cardiovascular surgery or the contrast agent exposure.

  • The determination of the GFR trajectory for CSA-AKI or CA-AKI

    Perform GFR testing on patients with AKI related to cardiovascular surgery or contrast agents to determine their trajectory

  • Perioperative changes in GFR for the early prediction and diagnosis of CSA-AKI

    Incorporate adult patients who meet the inclusion and exclusion criteria and are scheduled for cardiovascular surgery, and monitor their perioperative changes in GFR through GFR testing to achieve early prediction and diagnosis of CSA-AKI.

06

What researchers measure

Primary outcomes

  1. CSA-AKI and severe CSA-AKI

    Incidence of cardiac surgery-associated acute kidney injury (CSA-AKI), defined according to the KDIGO criteria based on postoperative changes in serum creatinine and incidence of severe cardiac surgery-associated acute kidney injury, defined as KDIGO Stage 2 or Stage 3 acute kidney injury.

    Time frame: Within 7 days after cardiovascular surgery

  2. Contrast-associated acute kidney injury

    Incidence of contrast-associated acute kidney injury, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on changes in serum creatinine following contrast media administration.

    Time frame: Within 72 hours after contrast media administration

Secondary outcomes

  1. Severe Acute Kidney Injury

    Incidence of severe acute kidney injury, defined as KDIGO stage 2 or stage 3 acute kidney injury.

    Time frame: Within 7 days after cardiac surgery or within 72 hours after contrast media administration

  2. Progression of AKI Stage

    Progression of acute kidney injury severity according to the KDIGO staging criteria from the initial diagnosis during follow-up.

    Time frame: From AKI diagnosis to 7 days after cardiac surgery or 72 hours after contrast media administration

  3. Acute Kidney Disease (AKD)

    Incidence of acute kidney disease, defined according to the Acute Disease Quality Initiative (ADQI) criteria.

    Time frame: From 7 days to 90 days after AKI onset

  4. Renal Replacement Therapy (RRT)

    Requirement for renal replacement therapy, including intermittent hemodialysis or continuous kidney replacement therapy.

    Time frame: Within 90 days after cardiac surgery or contrast media administration

  5. All-cause and Cardiovascular Mortality

    Incidence of all-cause mortality and cardiovascular mortality during follow-up.

    Time frame: Within 1 year after cardiac surgery or contrast media administration

  6. Major Adverse Cardiovascular Events (MACE)

    Composite incidence of major adverse cardiovascular events, including cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization for heart failure.

    Time frame: Within 1 year after cardiac surgery or contrast media administration

  7. New-onset Chronic Kidney Disease or CKD Progression

    Incidence of newly diagnosed chronic kidney disease or progression of pre-existing chronic kidney disease, based on KDIGO CKD criteria.

    Time frame: Within 1 year after cardiac surgery or contrast media administration

  8. Rate of Decline in Glomerular Filtration Rate

    Annualized decline in estimated glomerular filtration rate (eGFR) during follow-up.

    Time frame: From baseline to 1 year after cardiac surgery or contrast media administration

  9. Change in Glomerular Filtration Rate

    Change in glomerular filtration rate measured by transcutaneous fluorescence monitoring and/or estimated glomerular filtration rate compared with baseline.

    Time frame: From baseline to 90 days after cardiac surgery or contrast media administration

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases
    Beijing, Beijing Municipality 100037, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07749417
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Jul 17, 2026
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Aug 6, 2026

Study contacts

Jianfang Cai
Contact
caijfbj@126.com
+86 15801601007
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion